Canary Wharf Group (“CWG”) and Kadans Science Partner (“Kadans”) have appointed real estate advisory firms Cushman & Wakefield and JLL as leasing agents for the 800,000 sq ft commercial laboratory building they intend to develop to create a world leading health and life sciences cluster at Canary Wharf.
The 23-storey building will be delivered in 2026 and will be the largest commercial wet lab enabled life science building in Europe. Importantly, it will be a laboratory building at its core, with full flexibility allowing lab space on all floors.
The 3.3-hectare North Quay site is located on the doorstep of Canary Wharf’s new Elizabeth line station, providing excellent connectivity to central London and Heathrow. Designed by KPF, the new building will be developed to the highest sustainability and technological standards. The project will leverage Kadans’ experience of curating multi-let lab projects with vibrant communities in order to create a new campus under one roof, housing SME’s and academics as well as global healthcare and pharmaceutical companies.
Richard Archer, Managing Director, Canary Wharf Group, said: “The appointment of Cushman & Wakefield and JLL is a reflection of our commitment to assembling a best-in-class team to deliver the biggest and most innovative life sciences development in Europe. We already have a significant amount of interest from potential occupiers in relation to our plans and will aim to start leasing space concurrent with construction. At the same time, we will also look to build on the momentum of the recent leasing to Genomics England at One Canada Square, as we establish a major life science ecosystem Canary Wharf.”
James Sheppard Managing Director UK & Ireland at Kadans Science Partner added: “Both Cushman & Wakefield and JLL have first class specialist life science teams, who will bring exceptional expertise and experience that is highly complementary of our own intrinsic insight into the requirements and modus operandi of the life science and healthcare industry. We are targeting an official marketing launch of the new development at North Quay early next year.”
Paddy Shipp, Head of UK Life Sciences Agency at JLL said: “London is an extremely exciting market for the UK’s life science sector where we are seeing significant occupational demand for best-in-class lab space in London. This landmark development will be truly unique and JLL are thrilled to be working with the joint venture in bringing it forward in the heart of East London’s knowledge cluster.”
Jamie Renison, Head of Life Sciences Agency UK at Cushman & Wakefield, added: “This pioneering new development at North Quay will have a transformational effect on the life sciences sector in London, further enhancing the UK’s status as a centre for research, innovation and discovery. We are excited to be helping Canary Wharf Group and Kadans create the environment and ecosystem in which companies have everything they need to flourish and grow, using the strength and connectivity of our global life sciences platform to do so.”
Canary Wharf is already home to a number of leading healthcare and life sciences-focused organisations, including Genomics England, Barts Health NHS Trust, the Medicines and Healthcare Products Regulatory Agency, Medical Defence Union, General Pharmaceutical Council and NHS Transformation.
ENDS
For further information, please contact:
Richard Sunderland, Richard Stocks, Ciara Martin
FTI Consulting
T: 020 3727 1000
E: canarywharf@fticonsulting.com
Notes to Editors
About Canary Wharf Group:
Canary Wharf Group (CWG) is the developer of the largest urban regeneration project in Europe. CWG develops, manages and currently owns interests in approximately 9 million square feet of mixed-use space and over 1,100 Build to Rent apartments.
CWG is the largest sustainable developer in the UK and also excels operationally as it has purchased 100% electricity from renewable sources since 2012 and sent zero waste to landfill since 2009.
CWG has created a 24/7 city where people can live, work and thrive on the Canary Wharf estate and enjoy all the benefits: great transport links, access to green spaces and waterside living; and a wide range of amenities including an award-winning arts and events programme. Canary Wharf’s retail offering comprises over 300 shops, including grocery stores, pharmacies, health clubs, bars and restaurants, all within 15 minutes’ walk.
The Company’s current £2bn construction activity and pipeline includes more than 500k square feet NIA of commercial properties and over 2,300 new homes for sale and rent.
www.canarywharf.com
LinkedIn: @CanaryWharfGroup
Instagram: @canarywharflondon / @eastwintergarden / @woodwharf
TikTok: @canarywharflondon
Twitter: @YourCanaryWharf / @CanaryWharfGrp / @Level39CW / @Wood_Wharf
About Kadans Science Partner
Kadans Science Partner is the European leader investing in the development of ecosystems and real estate with a dedicated focus on the knowledge intensive sector. Kadans has invested across various specific areas, like agri-tech in Wageningen, life sciences in Leiden, and cell & gene therapy in Stevenage, UK. Kadans provides its tenants with an array of additional services tailored to their specific needs. In December 2020, Kadans was acquired by AXA IM Alts, which, as a long- term capital partner, has allowed us to significantly accelerate our growth.
Kadans is currently present on 23 campuses, in 7 countries, where it operates over 6 million sq ft of space for over 400 tenants, including start-ups, scale-ups, corporates, government bodies and educational institutes. Kadans has a solid view of the developments our tenants and partners are currently working on and which parties in our network could benefit from connecting.
www.kadans.com
Instagram: @kadanssciencepartner
Twitter: @KadansScience